Lamotrigine add-on therapy to venlafaxine treatment in adolescent-onset bipolar II disorder: a case report covering an 8-month observation period

Bildik, Tezan; Tamar, Müge; Korkmaz, Sevda; Gökçen, Sezen; Özbaran, Burcu; Erermiş, Serpil; Aydın, Cahide

doi:10.5414/cpp44198

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pediatric bipolar depression, several case reports describe the successful use of lamotrigine for periods of up to 8 months (66,67), as lamotrigine has now emerged as a first-line agent for adult bipolar depression. One study of 46 adolescents with manic or mixed episodes demonstrated reduced depressive symptoms following lamotrigine treatment (28).…”

Section: Lamotriginementioning

confidence: 98%

Management of Bipolar Disorder in Children and Adolescents

Patino¹,

Bruns²,

Witt³

et al. 2015

FOC

View full text Add to dashboard Cite

Treatment options for bipolar disorder have been primarily studied in adults. However, there is a growing body of research of these treatments in youths with bipolar disorder. Despite this there is still a huge gap in clinical trials performed on adults and children and as this manuscript will show, extrapolating results of adult studies doesn't necessarily translate to successful treatment in youths. Furthermore, although medication is the cornerstone of treatment in children and adolescents with bipolar disorder, psychosocial interventions are of paramount importance. The current manuscript will review the empirical evidence available for both pharmacological and psychosocial treatment strategies. In addition, evidence for the use of medications in different stages of bipolar disorder, including acute manic and mixed states and bipolar depression is addressed. The use of combination therapy, the treatment of pediatric bipolar disorder comorbid with other psychiatric conditions and the management of treatment resistant mania is also discussed.

show abstract

Section: Lamotriginementioning

confidence: 98%